Tradename: ABRYSVO
Proper Name: Respiratory Syncytial Virus Vaccine
Indication: Indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
Approval Date: 08/21/2023
Manufacturer: Pfizer Inc.
More: https://www.fda.gov/vaccines-blood-biologics/abrysvo